Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Dazodalibep in Sjogren Syndrome With Moderate-to-severe Systemic Disease Activity
jRCT2061230107Phase 3Active, not recruiting
- Sponsor
- Horizon Therapeutics
- Start
- May 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of dazodalibep in Sjögren's syndrome (3 arms), sponsored by Horizon Therapeutics. Primary endpoint: Change from baseline in ESSDAI score at Week 48. Started May 2024; status: active, not recruiting.
02
Drugs
dazodalibep
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on jRCT2061230107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230107.